The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19

Annamaria Mascolo1,2†, Cristina Scavone1,2†, Concetta Rafaniello1,2, Antonella De Angelis2, Konrad Urbanek2,3, Gabriella di Mauro1,2, Donato Cappetta2, Liberato Berrino2, Francesco Rossi1,2‡ and Annalisa Capuano1,2‡

1Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy, 2Department of Experimental Medicine, Section of Pharmacology “L. Donatelli”, University of Campania “Luigi Vanvitelli”, Naples, Italy, 3Department of Experimental and Clinical Medicine, Molecular and Cellular Cardiology, Magna Graecia University, Catanzaro, Italy

The renin-angiotensin-aldosterone system (RAAS) firstly considered as a cardiovascular circulating hormonal system, it is now accepted as a local tissue system that works synergistically or independently with the circulating one. Evidence states that tissue RAAS locally generates mediators with regulatory homeostatic functions, thus contributing, at some extent, to organ dysfunction or disease. Specifically, RAAS can be divided into the traditional RAAS pathway (or classic RAAS) mediated by angiotensin II (AII), and the non-classic RAAS pathway mediated by angiotensin 1–7. Both pathways operate in the heart and lung. In the heart, the classic RAAS plays a role in both hemodynamics and tissue remodeling associated with cardiomyocyte and endothelial dysfunction, leading to progressive functional impairment. Moreover, the local classic RAAS may predispose the onset of atrial fibrillation through different biological mechanisms involving inflammation, accumulation of epicardial adipose tissue, and electrical cardiac remodeling. In the lung, the classic RAAS regulates cell proliferation, immune-inflammatory response, hypoxia, and angiogenesis, contributing to lung injury and different pulmonary diseases (including COVID-19). Instead, the local non-classic RAAS counteracts the classic RAAS effects exerting a protective action on both heart and lung. Moreover, the non-classic RAAS, through the angiotensin-converting enzyme 2 (ACE2), mediates the entry of the etiological agent of COVID-19 (SARS-CoV-2) into cells. This may cause a reduction in ACE2 and an imbalance between angiotensins in favor of All that may be responsible for the lung and heart damage. Drugs blocking the classic RAAS (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) are well known to exert a cardiovascular benefit. They are recently under evaluation for COVID-19 for their ability to block All-induced lung injury altogether with drugs stimulating the non-classic RAAS. Herein, we discuss the available evidence on the role of RAAS in the heart and lung, summarizing all clinical data related to the use of drugs acting either by blocking the classic RAAS or stimulating the non-classic RAAS.

Keywords: renin-angiotensin-aldosterone system, heart, lung, COVID-19, inflammation
INTRODUCTION

The renin-angiotensin-aldosterone system (RAAS) is first considered a cardiovascular circulating hormonal system. It is now accepted also as a local tissue system that works synergistically or independently with the circulating one (Labandeira-Garcia et al., 2014; Mascolo et al., 2017). Evidence states that tissue RAAS locally generates mediators with homeostatic regulatory functions, thus contributing, to some extent, to organ dysfunction or disease (Rossi et al., 2016; Mascolo et al., 2020a; Mascolo et al., 2020b). The RAAS can be divided into the traditional RAAS pathway (or classic RAAS) mediated by angiotensin II (AII), and the non-classic RAAS pathway mediated by angiotensin 1–7 (A1-7). Both pathways are locally present in the heart and lung. In the heart, an enhancement of classic RAAS, at the expense of non-classic RAAS, can induce cardiac hypertrophy, fibrosis, and dysfunction leading to heart failure (HF) and atrial fibrillation (AF) (Rossi et al., 2016; Mascolo et al., 2020b). In the lung, the classic RAAS also regulates cell proliferation, immune-inflammatory response, hypoxia, and angiogenesis, contributing to lung injury and different pulmonary diseases (Mascolo et al., 2020a; Catarata et al., 2020). Instead, the local non-classic RAAS counteracts the classic RAAS effects exerting a protective action on both heart and lung. However, it is essential to notice that a component of the non-classic RAAS, the transmembrane angiotensin-converting-enzyme 2 (ACE2), localized on the lung alveolar epithelial cells, is a receptor mediating the viral entry of the severe acute respiratory syndrome coronavirus 1 (SARS-COV-1) and SARS-COV-2, responsible for the SARS and the coronavirus disease 2019 (COVID-19), respectively (Li et al., 2003; Turner et al., 2004; Hoffmann et al., 2020). Despite the main symptoms of COVID-19 are respiratory and flu-like symptoms, which can be complicated by lymphopenia and high levels of pro-inflammatory cytokines leading to acute respiratory distress syndrome (ARDS), organ failure, and disseminated coagulopathy (Guo et al., 2020); some patients also develop cardiovascular symptoms (Huang et al., 2020). In this view, it seems pertinent to summarize the evidence on the role of RAAS in cardiac diseases (such as HF and AF) and pulmonary diseases with a focus on COVID-19. Notably, drugs blocking the classic RAAS, well known to exert a cardiovascular benefit, are under evaluation for blocking AII-induced lung injury together with drugs stimulating the non-classic RAAS. Herein, we discuss the evidence on the role of RAAS in the heart and lung, summarizing all clinical data related to the use of drugs acting either by blocking the classic RAAS or stimulating the non-classic RAAS.

CLASSIC AND NON-CLASSIC RAAS

The main effector peptide of classic RAAS is the AII, whose synthesis starts with the cleavage of angiotensinogen into Angiotensinogen

![Classic and non-classic RAAS and its interaction with SARS-COV-2](https://example.com/figure1)

**FIGURE 1** Classic and non-classic RAAS and its interaction with SARS-COV-2. From Mascolo A, Scavone C, Rafaniello C, Ferrajolo C, Racagni G, Berrino L, Padisso G, Rossi F, Capuano A. Renin-Angiotensin System and Coronavirus disease 2019: A Narrative Review. Front Cardiovasc Med. 2020 Aug 11;7:143. doi: 10.3389/fcvm.2020.00143.
angiotensin I (AI) by the renin and then its conversion into AII by
the angiotensin-converting enzyme (ACE) (Figure 1) (Unger,
2002). However, AII can also be synthesized through pathways
that involve other enzymes like chymase, chymostatin-sensitive
angiotensin II-generating enzyme (CAGE), and cathepsin G
(Mascolo et al., 2020b). These alternative pathways play a role
in the local production of AII. In fact, in the heart, angiotensin
1–12 can be converted by chymase into AII, and this synthesis is
significant in inducing adverse left ventricular remodeling post-
myocardial infarction (Ahmad et al., 2014). Once synthesized,
AII can interact with three receptors (AT1, AT2, and
nonAT1nonAT2). AT1 and AT2 are G protein-coupled
receptors (Unger, 2002), while nonAT1nonAT2 is an
angiotensinase or an angiotensin clearance receptor
(Karamyan et al., 2010). The stimulation of the AT1 receptor
induces vasoconstriction, increases the release of catecholamines
and the synthesis of aldosterone (Unger, 2002), stimulates fibrosis
and inflammation, and reduces the activity of collagenses and
the expression of mitogen-activated protein kinase (MAPK)
(Mascolo et al., 2017; Mascolo et al., 2020b). The pro-
inflammatory action of AT1 receptors involves the down-
regulation of the NADPH oxidase expression in smooth
muscle cells, the production of reactive oxygen species (ROS),
and the activity of pro-inflammatory transcription nuclear factors
like nuclear factor-kappaB (NF-κB) and E26 transformation-
specific sequence (Ets) (Marchesi et al., 2008; Porreca et al.,
2017). Moreover, these receptors induce the release of tumor
tumor necrosis factor-α (TNF-α), the interleukin-6 (IL-6), and the
monocyte chemoattractant protein-1 (MCP-1) (Dandona et al.,
2007) and shift the macrophage phenotype toward the pro-
inflammatory M1 polarization state (Yamamoto et al., 2011).
On the contrary, the stimulation of AT2 receptors exerts a protective role by inducing anti-inflammatory, anti-oxidative,
and anti-fibrotic effects (Unger, 2002). Instead, the primary
mediator of non-classic RAAS is the A1-7, whose synthesis
can involve two pathways. One pathway starts with the
cleavage of AII into A1-7 by the carboxypeptidase ACE2. A second
pathway begins with the cleavage of AI into angiotensin
1–9 (A1–9) by ACE2 and its consecutive conversion into A1–7 by
ACE (Figure 1) (Mascolo et al., 2020b). ACE2 is classified into the
soluble form present in the plasma and a transmembrane form
existing locally in both the heart and lung (Mascolo et al., 2020a).
Both forms contribute to the generation of A1-7, which can
interact with the G protein-coupled receptor MAS1, promoting
the nitric oxide release (Fraga-Silva et al., 2008), Akt
phosphorylation (Dias-Peixoto et al., 2008), and anti-
inflammatory effects (da Silveira et al., 2010). Moreover, ACE
and ACE2 participate in the inflammation as components of a
local RAAS at sites infiltrated by monocytes/macrophages. Both
enzymes are expressed by human monocytes where metabolize
AI to multiple angiotensin peptides. In particular, classical
monocytes (CD14++CD16−) produce both AII and A1–9/
A1–7, whereas the non-classical subtype (CD14−CD16++)
produces mainly A1–7 (Rutkowska-Zapala et al., 2015).
Finally, the stimulation of MAS1 receptors on macrophages
can inhibit their polarization to inflammatory phenotype and the
release of pro-inflammatory cytokines (Mascolo et al., 2020b).

Thus, A1-7 can be considered a beneficial axis component that
exerts opposite effects to the classic RAAS (Santos et al., 2013).

THE ROLE OF RAAS IN THE HEART

It is recognized that the classic RAAS is involved in developing
cardiac diseases such as HF and AF, which are closely
interconnected. Atrial fibrillation’s key component is the
structural remodeling that breaks tissue microarchitecture and
disturbs ion currents and physiological cell-to-cell
interconnections, but its importance extends beyond this
arrhythmia. Atrial remodeling frequently corresponds with the
ventricular remodeling in HF, increasing the complexity of the
problem. Moreover, neurohormonal and structural alterations of
HF can increase the probability of developing and advancing AF,
and AF can favor incident HF development (Stewart et al., 2002;
Maisel and Stevenson, 2003). The pathophysiological
mechanisms of RAAS in these diseases are reported below.
The AII stimulates collagen synthesis and fibroblast
proliferation in the heart, inducing cardiac hypertrophy and
fibrosis, which are critical elements of the adverse ventricular
remodeling (Rossi et al., 2016; Mascolo et al., 2020b). Specifically,
the local cardiac production of AII has been associated with an
increase in myocardial mRNA expression of collagen I/III and
fibronectin (Fieltz et al., 2001). Moreover, AII can stimulate the
myocardial generation of aldosterone, which can also contribute
to the synthesis of collagen and to the local production of AII.
These effects drive the characteristics hemodynamics alterations
(Rossi et al., 2016). Additionally, other than inducing fibrosis, AII
can stimulate inflammatory processes and change the heart’s
electrophysiological properties (electrical cardiac remodeling) (Li
et al., 2001; Novo et al., 2008). These processes can influence the
onset of AF. Of note, up-regulation of AT1 receptors was found in
left atrial tissue of patients with lone AF or AF with underlying
mitral valve disease compared to patients in sinus rhythm. In
contrast, no difference was observed in the expression of AT2
receptors (Bolldt et al., 2003). AII exerts electrical cardiac
remodeling effects by shortening the atrial effective refractory
period and the action potential duration potentiating the slow
component of delayed rectifier K⁺ channels in guinea pig atrial
myocytes (Zankov et al., 2006). Finally, a more recent hypothesis
on the role of AII in inducing AF suggests that the classic RAAS
may mediate epicardial fat accumulation and inflammation,
which can, in turn, cause AF (Patel et al., 2016a). Epicardial
fat accumulation can induce AF through direct and indirect
pathophysiological mechanisms (Wong et al., 2017). The
direct mechanism consists of epicardial adipocytes’ infiltration
into the underlying atrial myocardium (Hatem and Sanders,
2014), while indirect mechanisms are: the release of
inflammatory adipokines (such as TNF-α, IL-6, and MCP-1),
ROS, and secrete matrix metalloproteinases 2 and 7, which can
stimulate atrial remodeling and fibrosis (Carnes et al., 2001;
Boixel et al., 2003; Conway et al., 2004; Malavazos et al., 2007;
Kourliouros et al., 2011; Smit et al., 2012; Venteclef et al., 2015);
the switch of macrophages from an anti-inflammatory M2 to a
pro-inflammatory M1 polarization state (Jung and Choi, 2014);
the activation of ganglionicated plexi located in the epicardial fat (Wong et al., 2017); the stimulation of AF triggers (Nagashima et al., 2012; Nakahara et al., 2014).

On the contrary, the non-classic RAAS exerts a protective role in the heart by reducing inflammation, fibrosis, and cardiac electrical remodeling along with vasodilation and the reduction of hypertrophy and thrombosis (Esposito et al., 2018; Santos et al., 2013). As anti-fibrotic effects, A1-7 has shown the ability to increase the mRNA expression of extracellular signal-regulated kinase-1 (ERK1/ERK2) (Liu et al., 2010). Moreover, the overexpression of ACE2 has been associated with a reduction in the expression of transient receptor potential melastatin 7, which is a Ca$^{2+}$ channel expressed on fibroblasts that can contribute to the fibrogenesis mediated by the transforming growth factor (TGF) (Zhou et al., 2017). In opposition, ACE2 knockout animal models showed a worse left ventricular remodeling in response to the AII-induced acute injury, suggesting a protective role of non-classic RAAS in the myocardium recovery (Kassiri et al., 2009). As mentioned above, A1-7 inhibits the pro-inflammatory macrophage polarization state and the release of pro-inflammatory cytokines (Souza and Costa-Neto, 2012). Moreover, the non-classic RAAS can reduce the inflammation of the epicardial adipose tissue. An increase of adipose tissue macrophages, pro-inflammatory cytokines (TNF-$\alpha$, IL-1$\beta$, IL-6), and iNOS was observed in ACE2 knockout mice (Patel et al., 2016b). Finally, A1-7 has shown the ability to prevent the ion recoil remodeling of AF in preclinical models (Liu et al., 2011). Based on the mechanisms mentioned above, a stimulation of the non-classic RAAS can benefit both AF and HF.

**Effects of Classic RAAS Blockers in Cardiac Diseases**

Classic RAAS blockers are renin inhibitors, ACE inhibitors, and Angiotensin Receptor Blockers (ARBs). Among them, ACE inhibitors and ARBs are widely used to treat cardiovascular diseases. Clinical evidence has also shown their potential for the prevention of AF (Novo et al., 2008; Mascolo et al., 2020b). Specifically, RAAS blockers effectively prevented primary AF in patients with early stage of HF and/or not severe hypertension. This is in accordance with their effect of blocking local inflammation and cardiac remodeling, which are expected to be at a maximum in patients at an early stage of the disease. Therefore, it is not surprising to find a lower efficacy of these drugs for the secondary prevention of AF and in populations of patients at a more advanced stage of the disease (Mascolo et al., 2020b).

The mechanisms mediated by ACE-inhibitors and ARBs for cardiac protection are the inhibition of atrial fibrosis and inflammation, the prevention of electrical cardiac remodeling, and the epicardial adipose tissue’s modulation. Concerning inflammation, many studies have demonstrated that ARBs and ACE-inhibitors are associated with anti-oxidative and anti-inflammatory effects. Specifically, these drugs can reduce pro-inflammatory mediators such as C-reactive protein, IL-6, MCP-1, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, NF-$\kappa$B, and ROS, and increase anti-inflammatory mediators such as the inhibitor of kB and IL-10 (Dandona et al., 2007). Some ARBs exert anti-inflammatory effects because they are agonists of the peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$). This intracellular nuclear hormone receptor controls the expression of pro-inflammatory genes through the inhibition of the AP-1 and NF-$\kappa$B transcription factors. Among ARBs, telmisartan (with a biphemyl tetrazole group) has a higher affinity to PPAR$\gamma$, followed by candesartan and losartan (Saavedra, 2012).

Regarding the prevention of electrical cardiac remodeling, RAAS blockers have shown the ability to prevent the shortening of the atrial effective refractory period (Nakashima et al., 2000), improve intra-atrial conduction (Wang and Li, 2018), and prolong the action potential duration (Zankov et al., 2006). Moreover, a preclinical study of dogs with ventricular tachypacing-induced congestive HF found that enalapril, an ACE-inhibitor, can reduce conduction abnormalities, atrial fibrosis, and ERK activation (Li et al., 2001; Moccia et al., 2015). Finally, ACE-inhibitors and ARBs may exert cardiac protection by inhibiting epicardial fat accumulation and downsizing epicardial adipocytes (Mori et al., 2007).

**Effects of Drugs Stimulating the Non-classic RAAS in Cardiac Diseases**

Drugs stimulating the non-classic RAAS, such as the human recombinant ACE2 and agonists of MAS1 receptors, are under investigation for cardiovascular diseases (Mascolo et al., 2017). Preclinical evidence in wild-type mice showed that human recombinant ACE2 reduced AII-induced cardiac remodeling and myocardial fibrosis. ACE2 reduced the transcription of fibronectin, TGF-$\beta$1, procollagen type I $\alpha$ 1, and procollagen type III $\alpha$ 1, the phosphorylation of the Janus kinase 2, extracellular signal-regulated 1/2, and the levels of protein kinase C-$\alpha$ and protein kinase C-$\beta$1 (Zhong et al., 2010). Moreover, the human recombinant ACE2 showed the ability to attenuate diabetic kidney injury, reduced blood pressure and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in Akita mouse models (Oudit et al., 2010). Finally, its administration showed a protective effect in murine models of AII-induced HF with preserved ejection fraction and pressure-overload mediated HF with reduced ejection fraction (Patel et al., 2017). Regarding clinical evidence, the human recombinant ACE2 has completed phase I (NCT00886353) and phase II (NCT01597635) clinical trials, and its administration was well tolerated with no evident cardiovascular effect in healthy subjects (Haschke et al., 2013). Among MAS1 receptor agonists investigated for treating cardiovascular diseases, there is the non-peptide compound AVE 0991 and the A1-7. AVE 0991 was studied in combination with a renin inhibitor (aliskiren) in rats with experimental hypertension and showed a synergistic effect in lowering the blood pressure (Singh et al., 2013). A1-7 has been investigated in a vector of hydroxypropyl-$\beta$-cyclodextrin. With this new formulation, designed to protect A1-7 from degradation and to increase its half-life through a slow-release,
A1-7 lowered the blood pressure in animal models (Bertagnolli et al., 2014). Moreover, A1–7 has shown a beneficial cardioprotective effect in various murine models of HF with reduced or preserved ejection fraction (Patel et al., 2017). Finally, clinical data on A1-7 in HF are lacking.

THE ROLE OF RAAS IN THE LUNG

The RAAS seems involved in the development of multiple lung diseases, such as idiopathic pulmonary fibrosis, sarcodeiosis, pulmonary hypertension, acute respiratory distress syndrome, lung cancer, and COVID-19 (Catarata et al., 2020; Mascolo et al., 2020a). An increased expression of ACE was observed in lung interstitium in several diseases, supporting the notion of a pulmonary local RAAS and a role for the AII in lung injury and fibrosis (Marshall, 2005). Both AT1 and AT2 receptors are present in the normal and pathological human lung (Catarata et al., 2020). The AT1 receptors were found on vascular smooth muscle cells, alveolar macrophages and in the stroma underneath the airway epithelium, while AT2 receptors were detected in bronchial epithelium and endothelial cells (Bullock et al., 2001). Physiological and pathophysiological effects of AII are mainly mediated through the activation of AT1 receptors (Chung et al., 1996). These receptors mediate vasoconstriction, cell proliferation, angiogenesis, and inflammation with increased pro-inflammatory cytokines, oxidative stress and fibrosis, inflammatory cell chemotaxis, and epithelial cell apoptosis (Kaparianos and Argyropoulou, 2011). Moreover, in vitro studies have demonstrated that the epithelial to mesenchymal transition (EMT) induced by TGF-β1 was associated with an increased expression of angiotensinogen and AT1 receptor in human lung fibroblasts (Abdul-Hafez et al., 2009; Renzoni et al., 2004; Uhal et al., 2007). Finally, the expression of TGF-β1 in human lung myofibroblasts was reduced by AT1 receptor blockade and associated with collagen synthesis inhibition (Uhal et al., 2007). In contrast, AT2 receptors were associated with opposite effects, although some pro-inflammatory effects were observed through the NF-kB pathway activation (Kaparianos and Argyropoulou, 2011). The impact of the classic RAAS in lung pathophysiology was also evident in studies that found inhibition of bleomycin-, γ irradiation-, amiodarone- and paraquat-induced pulmonary fibrosis with the administration of ACE inhibitors (captopril, enalapril, lisinopril, and perindopril) in rats (Mohammadi-Karakani et al., 2006; Molfenti et al., 2007; Wang et al., 2000). Moreover, a post hoc analysis of data from a phase 3, placebo-controlled, clinical trial showed a slower disease progression in patients with idiopathic pulmonary fibrosis treated with ACE inhibitors (Kreuter et al., 2019). Because AII and TGF-β1 may influence each other’s activity or act in synergy, the inhibition of both local mediators could delay the progression of lung fibrosis.

Regarding the non-classic RAAS, ACE2 was found in endothelial and smooth muscle cells, alveolar epithelial type I and II cells, and bronchial epithelial cells (Catarata et al., 2020). In the lung, ACE2 has multiple physiological roles: it exerts opposing effects to the classic RAAS as a negative regulator, and it is the receptor for SARS-COV-1 and SARS-COV-2 entry (Figure 1) (Gheblawi et al., 2020). As the negative regulator, the non-classic RAAS can reduce lung injury and prevent acute respiratory distress (Wösthen-Van Asperen et al., 2011; Chen et al., 2013; Meng et al., 2015). As the SARS-COV-2 receptor, ACE2 binds the SARS-COV-2’s glycosylated spike (S) protein. This bond is mediated by the human androgen-sensitive transmembrane serpine protease type 2 (TMPRSS2) (Mascolo et al., 2020a; Hoffmann et al., 2020) that cleaves the S protein into S1 and S2 subunits (South et al., 2020). The S1 subunit binds the ACE2 and facilitates the viral attachment, whereas the S2 subunit drives the membrane fusion and viral internalization in the pulmonary epithelium (Hoffmann et al., 2020). An important consideration that needs to be done for the pathophysiology of COVID-19 is related to the ACE2 internalization mediated by SARS-COV-2 that could potentially induce a reduction of ACE2 on cell surface and then determine the absence of a key factor important for the local pulmonary synthesis of A1-7. Indeed, an imbalance between AII and A1-7 levels may exacerbate the lung injury caused by SARS-COV-2, contributing to the reduction of the pulmonary function and the increase of fibrosis and inflammation (Triassi et al., 2019; South et al., 2020).

In conclusion, a complete understanding of the role of RAAS in the pulmonary inflammation and fibrosis is fundamental and may open new therapeutic possibilities for the treatment of respiratory diseases, including COVID-19.

Effects of Classic RAAS Blockers in the COVID-19

The use of RAAS blockers (ACE-inhibitors and ARBs) in COVID-19 patients has been object of discussion during the last year. First, evidence suggested that RAAS blockers may contribute to more adverse health outcomes by increasing the expression of ACE2 mRNA and then potentiating the virulence of SARS-COV-2 (Vaduganathan et al., 2020; Zheng et al., 2020). However, today, there is no study suggesting this association. Even if there was such association, there is no evidence demonstrating a causal relationship between the ACE2 activity and the SARS-COV-2 associated mortality (Kuster et al., 2020).

Another hypothesis considers the ability of SARS-COV-2 to enter any tissue expressing the ACE2, including the heart or other cardiovascular tissues (South et al., 2020). By this mechanism, SARS-COV-2 can induce a reduction of ACE2 in favor of the classic RAAS (increase in AII) that can cause heart damage, which might be even worse in patients with underlying cardiovascular diseases (South et al., 2020; Yousif et al., 2012). However, in this scenario, the RAAS blocker could be protective and beneficial for preventing AII-induced cardiac damage. As RAAS blocker are known to determine clinical benefits, another vital aspect to be considered is the potential damage when a RAAS blocker therapy is stopped in a patient with a stable cardiovascular condition (Mascolo et al., 2020a).

Data available on this topic come from observational studies that found no association between the use of ARBs or ACE-inhibitors with COVID-19 diagnosis (Gnavi et al., 2020; Mancia et al., 2020), admission to hospital for COVID-19 (de Abajo et al.,
**TABLE 1 |** Characteristics of ongoing clinical trials on the continuation or suspension of RAAS blockers in patients with COVID-19, and on the efficacy of ACE inhibitors, ARBs, angiotensin 1-7, and ACE2 for COVID-19.

| Clinical trial number | Clinical phase | Study design | Arms | Estimated enrollment | Primary outcome | Estimated study completion date |
|-----------------------|---------------|--------------|------|----------------------|----------------|-------------------------------|
| NCT04351581           | Not specified | Randomized, single mask, parallel assignment trial | Experimental: Continuation. The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissible for the clinician to stop treatment if necessary e.g., due to hypotension.<br> Experimental: Discontinuation. The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment. | 215 | 1. Days alive and out of hospital within 14 days after recruitment | December 2020 |
| NCT04353596           | 4             | Randomized, open label, parallel assignment trial | Experimental arm: Stopping/ replacing ACEi/ARB. Chronic treatment with ACEi or ARB will be stopped or replaced.<br> Control arm: No intervention, which means further treatment with ACEi or ARB. | 208 | 1. Combination of maximum sequential organ failure assessment (SOFA) score and death at 30 days<br> 2. Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death at 30 days | May 15, 2022 |
| NCT04329195           | 3             | Randomized, open label, parallel assignment trial | Experimental arm: discontinuation of RAAS blocker therapy.<br> Active Comparator arm: continuation of RAAS blocker therapy | 554 | 1. Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first) | August 9, 2020 |
| NCT04351724 substudy  | 2/3           | Randomized, open label, parallel assignment trial | Experimental arm: candesartan at 4 mg once daily and titrated to normotension<br> Active Comparator arm: non-RAAS antihypertensive agents titrated to normotension. Those with normal blood pressure may be controlled without further treatment.<br> Experimental arm: losartan (50 mg daily, oral)<br> Control arm: placebo (microcrystalline methylcellulose, gelatin capsule, oral) | 500 | 1. Sustained improvement (>48h) of one point on the WHO Scale within 29 days (daily evaluation) | December 31, 2020 |
| NCT04312009           | 2             | Randomized, quadruple mask, parallel assignment trial | | 200 | 1. Difference in Estimated Positive End-expiratory Pressure (PEEP adjusted) P/F Ratio at 7 days. Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SatO2; FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0 | April 1, 2021 |
| Clinical trial number | Clinical phase | Study design | Arms | Estimated enrollment | Primary outcome | Estimated study completion date |
|-----------------------|----------------|--------------|------|----------------------|----------------|--------------------------------|
| NCT04311177          | 2              | Randomized, quadruple mask, parallel assignment trial | Experimental arm: losartan (25 mg daily, oral) Comparator arm: placebo (microcrystalline methylcellulose, gelatin capsule, oral) | 580 | 1. Hospital Admission within 15 days. Outcome reported as the number of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization | April 1, 2021 |
| NCT04328012          | 2/3            | Randomized, quadruple mask, parallel assignment trial | Experimental arm: lopinavir/ritonavir (400 mg/200 mg, oral, BID X 5–14 days depending on availability) Experimental arm: hydroxychloroquine (400 mg BID on Day 0, and 200 mg BID Days 1–4, days 1–13 if available) Experimental arm: losartan (25 mg, oral, daily X 5–14 days depending on availability) Comparator arm: placebo (BID X 14 days) | 4000 | 1. National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS) at 60 days. Difference in NCOSS scores between the different treatment groups | April 1, 2021 |
| NCT04335786          | 4              | Randomized, quadruple mask, parallel assignment trial | Experimental arm: valsartan for 14 days at a dosage and frequency titrated to blood pressure with 80 mg or 160 mg tablets up to a maximum dose of 160 mg b.i.d Comparator arm: placebo for 14 days (matching 80 mg or 160 mg placebo tablets at a dosage and frequency titrated to systolic blood pressure) Comparator arm: placebo (BID X 14 days) | 651 | 1. First occurrence of intensive care unit admission, mechanical ventilation or death within 14 days. Death is defined as all-cause mortality | December 2021 |
| NCT04360551          | 2              | Randomized, triple mask, parallel assignment trial | Experimental arm: telmisartan (40 mg, oral, daily X 21 days) Comparator arm: placebo (once daily X 21 days) | 40 | 1. Maximum clinical severity of disease over the 21 day period of study. Based on a modified World Health Organization (WHO) COVID-19 7-point ordinal scale 1. All-cause mortality up to 28 days after randomization in Non-Critically Ill Patients with SARS-COV-2 Pneumonia | June 30, 2021 |
| NCT04428268          | 2              | Randomized, double mask, parallel assignment trial | Experimental: chloroquine phosphate 450 mg orally every 12 hrs plus losartan 25 mg orally every 12 hrs Comparator arm: chloroquine phosphate 450 mg every 12 h orally | 20 | 1. Organ failures assessed on the SOFA score on day 7 post-inclusion | August 30, 2020 |
| NCT04643691          | 2              | Randomized, open label, parallel assignment trial | Experimental arm: losartan 50 mg and spironolactone 25 mg (oral) Comparator arm: usual care of COVID-19 infection in intensive care | 90 | 1. Mortality at 28 days | October 30, 2022 |
| NCT04606663          | 3              | Randomized, open label, parallel assignment trial | Experimental arm: losartan 25 mg oral increased to 50 mg after 24 h and then increased to a max dose of 100 mg after another 24 h, dependent on tolerance (for up max of 3 months) Comparator arm: usual care for duration of hospitalization for up to 3 months if still hospitalized | 1372 | 1. Mortality at 28 days | June 30, 2021 |

(Continued on following page)
TABLE 1 | Continued Characteristics of ongoing clinical trials on the continuation or suspension of RAAS blockers in patients with COVID-19, and on the efficacy of ACE inhibitors, ARBs, angiotensin 1-7, and ACE2 for COVID-19.

| Clinical trial number | Clinical phase | Study design | Arms | Estimated enrollment | Primary outcome | Estimated study completion date |
|------------------------|----------------|--------------|------|-----------------------|----------------|-------------------------------|
| NCT04447235            | 2              | Randomized, double mask, parallel assignment trial | Experimental arm: a single dose of 12 mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50 mg orally once daily for 15 consecutive days  
Comparator arm: ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days | 176 | 1. Incidence of severe complications due COVID-19 infection at 28 days | February 2021 |
| NCT04340557            | 4              | Randomized, open label, parallel assignment trial | Experimental arm: standard of care plus losartan to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 210 if confident the subject will tolerate  
Comparator arm: standard of care | 200 | 1. Number of subjects requiring transfer into ICU for mechanical ventilation due to respiratory failure at 45 days | December 31, 2020 |
| NCT04335123            | 1              | Open label, single group trial | Experimental arm: losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy | 50 | 1. Number of participants with treatment-related adverse events as assessed by protocol definition of adverse event at 14 days | August 17, 2020 (results not published yet) |
| NCT04355936            | 4              | Randomized, open label, parallel assignment trial | Experimental arm: 80 mg telmisartan twice daily plus standard care  
Comparator arm: standard care  
Experimental arm: 200 mg of hydroxychloroquine twice a day during 14 days  
Experimental arm: 250 mg of azithromycin twice a day during 14 days  
Experimental arm: 40 mg of telmisartan twice a day during 14 days  
Comparator arm: usual Care (no intervention) | 400 | 1. Serum C reactive protein levels at days 5 and 8 | November 30, 2020 (results not published yet) |
| NCT04359963            | 3              | Randomized, open label, parallel assignment trial | Experimental arm: telmisartan 40 mg daily plus standard care  
Comparator arm: standard care | 1600 | 1. Two-weeks survival rate | June 1, 2021 |
| NCT04510662            | 2              | Randomized, open label, parallel assignment trial | Experimental arm: telmisartan 40 mg daily plus standard care  
Comparator arm: standard care | 60 | 1. Death as all-cause mortality at 30 days.  
2. Occurrence of mechanical ventilation at 14 days | April 2021 | (Continued on following page) |
| Clinical trial number | Clinical phase | Study design | Arms | Estimated enrollment | Primary outcome | Estimated study completion date |
|-----------------------|----------------|--------------|------|----------------------|-----------------|---------------------------------|
| NCT04466241           | 2/3            | Randomized, open label, parallel assignment trial | Experimental arm: lopinavir boosted by ritonavir 200mg/50mg (2 tablets morning and evening from Day 1 to Day 10) plus telmisartan 40 mg (1 tablet daily from Day 1 to Day 10) Experimental arm: lopinavir boosted by ritonavir 200mg/50mg (2 tablets morning and evening from Day 1 to Day 10) plus atorvastatin 20 mg (1 tablet daily from Day 1 to Day 10) Comparator arm: lopinavir boosted by ritonavir 200mg/50mg (2 tablets morning and evening from Day 1 to Day 10) Comparator arm: telmisartan (20 mg) during 10 days Comparator arm: ciclesonide (160 µg) during 10 days Comparator arm: vitamin supplement during 10 days | 294 | 1. Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11 | March 26, 2021 |
| NCT04356495           | 2/3            | Randomized, open label, parallel assignment trial | Experimental arm: telmisartan (20 mg) during 10 days Experimental arm: ciclesonide (160 µg) during 10 days Comparator arm: vitamin supplement during 10 days | 615 | 1. Proportion of participants who had a Grade 3 or 4 adverse event at day 14 2. Proportion of participants with an occurrence of death at day 14 3. Proportion of participants who had an indication for oxygen therapy at day 14 4. Proportion of participants who had an indication for hospitalization at day 14 | August 31, 2021 |
| NCT04583228           | 1              | Randomized, quadruple mask, sequential assignment trial | Experimental arm (sequence 1): HLX71 2.5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71 Experimental arm (sequence 2): HLX71 5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71 Experimental arm (sequence 3): HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71 Experimental arm (sequence 4): HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71 | 40 | 1. Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0 at 28 days 2. The proportion of subjects undergoing DLT events in each dose cohorts during the DLT observation period a days 1–7 | May 31, 2021 |
| NCT04332666           | 2/3            | Randomized, triple mask, parallel assignment trial | Experimental arm: A1-7 infusion (venous) of 0.2 mcg/Kg/h for 48 h Comparator arm: placebo | 60 | 1. Composite outcome of mortality and necessity of mechanical ventilation at 28 days | June 15, 2021 |
| NCT04605887           | 2              | Randomized, triple mask, parallel assignment trial | Experimental arm: A1-7 subcutaneously 500 mcg/kg/day Comparator arm: NaCl 0.9% subcutaneously 2.0 cc once a day | 120 | 1. Need for mechanical ventilation from randomization to 30 days | April 2024 |
TABLE 1 | (Continued) Characteristics of ongoing clinical trials on the continuation or suspension of RAAS blockers in patients with COVID-19, and on the efficacy of ACE inhibitors, ARBs, angiotensin 1-7, and ACE2 for COVID-19.

| Clinical trial number | Clinical phase | Study design | Arms | Estimated enrollment | Primary outcome | Estimated study completion date |
|-----------------------|----------------|--------------|------|----------------------|----------------|-------------------------------|
| NCT04401423           | 2              | Randomized, triple mask, parallel assignment trial | Experimental arm: A1-7 at one 3h dosage (0.5 mg/kg), intravenously, for 10 days consecutively | 100 | 1. Change of serum creatinine at day 1 and day 10 | December 2021 |
|                       |                |              | Comparator arm: placebo at one 3h dosage (0.5 mg/kg), intravenously, for 10 days consecutively | | 2. Number of participants requiring intubation and ventilatory support at day 10 | |
| NCT04570501           | 1/2            | Randomized, double mask, parallel assignment trial | Experimental arm: A1-7 for 7 days, administered by continuous intravenous (IV) infusion | 160 | 1. Time to recovery up to 29 days | June 2021 |
|                       |                |              | Comparator arm: placebo for 7 days | | | |
| NCT04633772           | 1/2            | Randomized, quadruple mask, parallel assignment trial | Experimental arm: A1-7 intravenous | 130 | 1. Supplemental oxygen-free days (SOFDs) at 28 days | February 28, 2021 |
|                       |                |              | Comparator arm: placebo (NaCl 0.9%) | | | |
| NCT04364893           | Not reported   | Randomized, open label, parallel assignment trial | Experimental arm: maintenance of ARBs and ACE-inhibitors | 700 | 2. Median days alive and out of the hospital at 30 days | December 1, 2020 |
|                       |                |              | Comparator arm: suspension of ARBs and ACE-inhibitors | | | |

Several clinical trials (ClinicalTrials.gov identifier, NCT04351581, NCT04353596, NCT04329195, NCT04351724) are ongoing to evaluate the clinical benefit of continuing or not the treatment with RAAS blockers in patients with COVID-19. Besides, based on the organ protective effects of RAAS blockers, many studies are ongoing to investigate their efficacy in patients with COVID-19. The beneficial effects of ACE inhibitors and ARBs is hypothesized to be related to the block of the classic RAAS in favor of the ACE2/A1-7 pathway as demonstrated in experimental studies (Chappell, 2016; Santos et al., 2019). In this regard, several clinical trials are ongoing to investigate the role of losartan (NCT04312009, NCT04311177, NCT04328012, NCT04428268, NCT04643691, NCT04605653, NCT04447235, NCT04340557, NCT04335123), valsartan (NCT04335786), and telmisartan (NCT04360551, NCT04355936, NCT04359953, NCT04510662, NCT04466241, NCT04356495) for the treatment of COVID-19 (Table 1).

Effects of Drugs Stimulating the Non-classic RAAS in the COVID-19

Considering the beneficial effects of the non-classic RAAS in the heart and lung, which seems in part lacking in patients with COVID-19, hypotheses were advanced on the potential therapeutic approach of restoring the ACE2/A1-7 pathway. Preclinical evidence showed that the infusion of A1-7 improved oxygenation, and reduced inflammation and fibrosis in two ARDS models (Wösten-Van Asperen et al., 2011; Zambelli et al., 2015; Cuomo et al., 2017). Moreover, the therapy with the soluble human recombinant ACE2 reversed the lung-injury process induced by other viral infections (Zou et al., 2014; Gu et al., 2016). It is crucial to notice that by administering the

2020), or COVID-19 severity (Reynolds et al., 2020). Moreover, another large observational study that compared the use of ACE-inhibitors and ARBs with active control (calcium channel blockers, and thiazide or thiazide-like diuretics) found no association between COVID-19 diagnosis and ACE-inhibitor or ARB use, and no significant difference between drug classes for the risk of hospital admission with COVID-19, hospital admission with pneumonia, acute respiratory distress syndrome, acute kidney injury, or sepsis across all comparisons (Reynolds et al., 2020). Finally, a cross-sectional, observational, multicenter, nationwide Italian study found that ACE inhibitors or other antihypertensive agents did not affect the outcome of COVID-19 (Iaccarino et al., 2020).

Regarding mortality, two observational studies found similar mortality rates between the use of RAAS blockers and non-RAAS blockers in COVID-19 patients (Gao et al., 2020; Jung et al., 2020). One retrospective study showed a lower risk of COVID-19 mortality in hospitalized patients with COVID-19 and hypertension who received ACE inhibitor/ARB than those who did not receive this treatment (Zhang et al., 2020). However, as recently reported in the preliminary results of a randomized trial (BRACE CORONA, NCT04364893), presented at the European Society of Cardiology Congress, the use of RAAS blockers was not associated with a beneficial effect, but considering that mortality was very low (2.7–2.8%) in the trial its validity is under question (de Abajo, 2020).

Scientific Societies recommend continuing the treatment with the usual anti-hypertensive agent in patients with COVID-19 and not stopping the RAAS inhibitor therapy as no evidence suggests so (American Heart Association, 2020; European Society of Cardiology, 2020; Italian Society of Cardiology, 2020; Italian Society of Hypertension, 2020; Italian Society of Pharmacology, 2020).
soluble ACE2, it is possible to stimulate the protective non-classic RAAS without increasing the transmembrane ACE2, avoiding potentiating the viral entry into cells.

Clinical evidence on the role of the non-classic RAAS in COVID-19 is scarce. A phase 2 clinical trial showed that the infusion of ACE2 safely reduced the level of AII in patients with ARDS. However, this trial had no enough power to show efficacy in pulmonary function improvement (Khan et al., 2017). There is an ongoing phase 1 clinical trial (NCT04583228) aiming to evaluate safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of the human recombinant ACE2-Fc fusion protein (HLX71) in healthy subjects. Finally, several clinical trials are ongoing to assess efficacy and safety of A1-7 infusion in COVID-19 patients (NCT04332666, NCT04605887, NCT04401423, NCT04570501, and NCT04633772). Characteristics of the aforementioned ongoing studies are shown in Table 1.

CONCLUSION

The classic RAAS plays an important role in the pathophysiology of cardiac diseases, while the non-classic RAAS exerts cardioprotective effects. Classic RAAS blockers are widely used for their efficacy in cardiovascular diseases and benefit from preventing primary AF. These drugs are also under consideration for preventing AII-induced lung injury. Indeed, many clinical trials are ongoing to evaluate their use in COVID-19. The rationale for using such drugs in COVID-19 is related to the imbalance between AII and A1-7 in favor of AII that can be caused by SARS-COV-2 internalization. A reduction in ACE2 can indeed further contribute to pulmonary function deterioration and myocardial damage. Moreover, for patients with COVID-19 already in treatments with RAAS blockers, Scientific Societies recommend not to suspend this treatment. Finally, clinical trials are ongoing to evaluate the beneficial pulmonary effect of restoring the ACE2/A1-7 pathway in COVID-19 patients.

REFERENCES

Abdul-Hafez, A., Shu, R., and Uhal, B. D. (2009). JunD and HIF-1α Mediate Transcriptional Activation of Angiotensinogen by TGF-β1 in Human Lung Fibroblasts. FASEB J. 23, 1655–1662. doi:10.1096/fj.08-114611
Ahmad, S., Varagic, J., Groban, L., Dell’Italia, L. J., Nagata, S., Kon, N. D., et al. (2014). Angiotensin-(1-12): A Chymase-Mediated Cellular Angiotensin II Substrate. Curr. Hypertens. Rep. 16, 429. doi:10.1007/s11906-014-0429-9
American Heart Association (2020). HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19
Bertagnolli, M., Casali, K. R., De Sousa, F. B., Rigatto, K., Becker, L., Santos, S. H. S., et al. (2003). Fibrosis of the Left Atria during Progression of Heart Failure Is an Endoderm Derived Glands. Mol. Cell Endocrinol. 207, 20–27. doi:10.1016/j.mce.2003.11.006
Boixel, C., Fontaine, V., Rücker-Martin, C., Milliez, P., Louedec, L., Michel, J.-B., et al. (2003). Fibrosis of the Left Atria during Progression of Heart Failure Is Associated with Increased Matrix Metalloproteinases in the Rat. J. Am. Coll. Cardiol. 42, 336–344. doi:10.1016/S0735-1097(03)00578-3
Boldt, A., Wetzel, U., Weigl, J., Garbade, J., Lauscha, J., Hindrichs, G., et al. (2003). Expression of Angiotensin II Receptors in Human Left and Right Atrial Tissue in Atrial Fibrillation with and without Underlying Mitral Valve Disease. J. Am. Coll. Cardiol. 42, 1785–1792. doi:10.1016/j.jacc.2003.07.014
Bullock, G. R., Steyaert, I., Bílé, G., Carey, R. M., Kips, J., De Paepe, B., et al. (2001). Distribution of Type-1 and Type-2 Angiotensin Receptors in the Normal Human Lung and in Lungs from Patients with Chronic Obstructive Pulmonary Disease. Histochem. Cell Biol. 115, 117–124. doi:10.1007/s004180000235
Carnes, C. A., Chung, O., Ribeiro, R., Oliveira, M. J., Robalo Cordeiro, C., and Medeiros, R. (2020). Renin-angiotensin System in Lung Tumor and Microenvironment Interactions. Cancers. 12, 1457–1524. doi:10.3390/cancers12061457
Chappell, M. C. (2016). Biochemical Evaluation of the Renin-Angiotensin System: The Good, Bad, and Absolute? Am J Physiol Heart Circ Physiol. 310, H137–H152. doi:10.1152/ajpheart.00618.2015
Chen, L.-N., Yang, X.-H., Nissen, D. H., Chen, Y.-Y., Wang, L.-J., Wang, J.-H., et al. (2013). Dysregulated Renin-Angiotensin System Contributes to Acute Lung Injury Caused by Hind-Limb Ischemia-Reperfusion in Mice. Shock. 40, 420–429. doi:10.1097/SHK.0b013e3182e6953e
Chung, O., Kühl, H., Stoll, M., and Unger, T. (1998). Physiological and Pharmacological Implications of A1 versus A2 Receptors. Kidney Int. Suppl. 67, S95–S99. doi:10.1046/j.1523-1755.1998.06719.x
Conway, D. S. G., Buggins, P., Hughes, E., and Lip, G. Y. H. (2004). Prognostic Significance of Raised Plasma Levels of Interleukin-6 and C-Reactive Protein in Atrial Fibrillation. Am. Heart J. 148, 462–466. doi:10.1016/j.ahj.2004.01.026
Cuomo, D., Porreca, L., Colbells, G., Tarallo, R., Nassa, G., Falco, G., et al. (2017). Carcinogenic Risk and Bisphenol A Exposure: A Focus on Molecular Aspects in Endoderm Derived Glands. Mol. Cell Endocrinol. 457, 20–34. doi:10.1016/j.mce.2017.01.027
da Silva, K. D., Coelho, F. M., Vieira, A. T., Sachs, D., Barroso, L. C., Costa, V. V., et al. (2010). Anti-inflammatory Effects of the Activation of the Angiotensin-(1-7) Receptor, MAS, in Experimental Models of Arthritis. J. I. 185, 5569–5576. doi:10.4049/jimmunol.1000314
Dandonada, P., Dhindsa, S., Ghanim, H., and Chaudhuri, A. (2007). Angiotensin II and Inflammation: The Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockade. J. Hum. Hypertens. 21, 20–27. doi:10.1038/sj.jhh.1002101
de Abajo, F. J. (2020). Renin–angiotensin System Inhibitors and COVID-19: Overwhelming Evidence against an Association. Lancet Digit. Heal. 3, e70–e71. doi:10.1016/S2589-7500(20)30294-6
de Abajo, F. J., Rodriguez-Martín, S., Lerma, V., Meja-Abril, G., Aguilar, M., García-Luque, A., et al. (2020). Use of Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19 Requiring Admission to Hospital: a Case–Population Study. Lancet. 395, 1705–1714. doi:10.1016/S0140-6736(20)31030-8

AUTHOR CONTRIBUTIONS

Drafting the work and revising it for important intellectual content: AM, CS, CR, AD, KD, GC, LB, FR, AC. Final approval of the version to be published: AM, CS, CR, AD, KD, GC, LB, FR, AC. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately discussed: AM, CS, CR, AD, KD, GC, LB, FR, AC. Developed the concept and designed the study: FR and AC. Wrote the paper: AM and CS.
by Captopril or by a Caspase Inhibitor. Am. J. Physiology-Lung Cell Mol. Physiol. 279, L143. doi:10.1152/apllung.2000.279.1.L143

Wang, X. and Li, G. (2018). Irbesartan Prevents Sodium Channel Remodeling in a Canine Model of Atrial Fibrillation. J. Renin Angiotensin Aldosterone Syst. 19, 147032031875526. doi:10.1177/1470320318755269

Wong, C. X., Ganesan, A. N., and Selvanayagam, J. B. (2017). Epicardial Fat and Atrial Fibrillation: Current Evidence, Potential Mechanisms, Clinical Implications, and Future Directions. Eur. Heart J. 38, 259–260. doi:10.1093/eurheartj/ehw045

Wösten-van Asperen, R. M., Lutter, R., Specht, P. A., Moll, G. N., Van Woensel, J. B., Van Der Loos, C. M., et al. (2011). Acute Respiratory Distress Syndrome Leads to Reduced Ratio of ACE/ACE2 Activities and Is Prevented by Angiotensin-(1-7) or an Angiotensin II Receptor Antagonist. J. Pathol. 225, 618–627. doi:10.1002/path.2987

Yamamoto, S., Yancey, P. G., Zuo, Y., Ma, L.-J., Kasada, R., Fogo, A. B., et al. (2011). Macrophage Polarization by Angiotensin II-type 1 Receptor Aggravates Renal Injury-Acceleration of Atherosclerosis. Arterioscler Thromb. Vasc. Biol. 31, 2856–2864. doi:10.1161/ATVBAHA.111.237198

Yousif, M. H. M., Dhaunsi, G. S., Makki, B. M., Qabazard, B. A., Akhtar, S., and Benter, I. F. (2012). Characterization of Angiotensin-(1-7) Effects on the Cardiovascular System in an Experimental Model of Type-1 Diabetes. Pharmacol. Res. 66, 269–275. doi:10.1016/j.phrs.2012.05.001

Zambelli, V., Bellani, G., Borsa, R., Pozzi, F., Grassi, A., Scanziani, M., et al. (2015). Angiotensin-(1-7) Improves Oxygenation, while Reducing Cellular Infiltrate and Fibrosis in Experimental Acute Respiratory Distress Syndrome. JCMs 3, doi:10.1186/s40635-015-0044-3

Zankov, D. P., Omatsu-Kanbe, M., Isono, T., Toyoda, F., Ding, W.-G., Matsushima, H., et al. (2006). Angiotensin II Potentiates the Slow Component of Delayed Rectifier K + Current via the at 1 Receptor in Guinea Pig Atrial Myocytes. Circulation. 113, 1278–1286. doi:10.1161/CIRCULATIONAHA.104.530592

Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J. J., Xie, J., et al. (2020). Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19. Circ. Res. 126, 1671–1681. doi:10.1161/CIRCRESAHA.120.31713410.1161/circresaha.120.317242

Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., and Xie, X. (2020). COVID-19 and the Cardiovascular System. Nat. Rev. Cardiol. 17, 259–260. doi:10.1038/s41569-020-0360-5

Zhong, J., Basu, R., Guo, D., Chow, F. L., Byrns, S., Schuster, M., et al. (2010). Angiotensin-converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation 122, 717–728. doi:10.1161/CIRCULATIONAHA.110.955369

Zhou, T., Han, Z., Gu, J., Chen, S., Fan, Y., Zhang, H., et al. (2017). Angiotensin-converting Enzyme-2 Overexpression Improves Atrial Electrical Remodeling through TRPM7 Signaling Pathway. Oncotarget. 8, 78726–78733. doi:10.18632/oncotarget.20221

Zou, Z., Yan, Y., Shu, Y., Gao, R., Sun, Y., Li, X., et al. (2014). Angiotensin-converting Enzyme 2 Protects from Lethal Avian Influenza A H5N1 Infections. Nat. Commun. 5, 3594. doi:10.1038/ncomms4594

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mascolo, Scavone, Rafanelli, De Angelis, Urbanek, di Mauro, Cappetta, Berrino, Rossi and Capuano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.